P&G Asks FDA To Make Prilosec The Standard For OTC PPI Claims
This article was originally published in The Tan Sheet
Executive Summary
Procter & Gamble is asking FDA to develop class labeling for OTC proton pump inhibitors that would effectively preclude all products in the category from claiming greater efficacy than P&G's Prilosec OTC
You may also be interested in...
FDA Denies P&G Petition For OTC Proton Pump Inhibitor Class Labeling
FDA's rejection of a Procter & Gamble citizen petition seeking class labeling for OTC proton pump inhibitors clears a roadblock for Schering-Plough's Zegerid to potentially make an "immediate release" claim
Prevacid Initial Launch Efforts To Focus On Switching Prescription Users
Novartis plans to prioritize converting patients currently treated with prescription Prevacid when the proton pump inhibitor becomes available over-the-counter, rather than winning over Prilosec OTC users, a Novartis executive said
Retailers’ Private Label Push Eats Into Name Brand Profits
Retailers are pushing store brands more aggressively and taking market share from name brands as more consumers seek savings in response to the recession